HAMS-AB / Rise Therap - LARVOL DELTA

Increasing gut short-chain fatty acids protects intestinal barrier function but does not spare muscle glycogen or impact aerobic performance. (PubMed, J Physiol) - "Using a randomized, double-blind, crossover design 12 active men (age 18-30 years; 40.0 ± 7.1 mL/kg/min) performed prescribed exercise and consumed a provided diet supplemented with acetylated and butyrylated high-amylose maize starch engineered to deliver SCFA to the colon (HAMS-A/B) or low-amylose maize starch (LAMS) for 7 days, separated by a 2 week washout...Increasing colonic and systemic SCFA availability preserved intestinal barrier function but did not impact glucose turnover, alter protein expression in muscle or spare muscle glycogen during endurance exercise. Increasing colonic and systemic SCFA availability did not impact aerobic endurance performance."

Clinical • Journal

Gut Microbiota and Hypertension: Mechanisms, Drug Interactions, and Translational Directions for Individualized Therapy. (PubMed, Int J Gen Med) - "Human interventional evidence remains preliminary: colon-targeted acetylated and butyrylated high-amylose maize starch increased circulating SCFAs and reduced 24-hour systolic BP by approximately 5-6 mmHg in a small, short-duration trial of untreated essential hypertension, whereas probiotics and prebiotics generally show modest BP reductions of approximately 1-3 mmHg systolic and 1-2 mmHg diastolic in meta-analyses. These findings support microbiota-informed hypertension research and risk stratification, but clinical implementation, particularly in well-defined RHT populations, remains investigational."

Journal • Review • Cardiovascular • Hypertension

Microbial production of short-chain fatty acids attenuates long-term neurologic impairment after traumatic brain injury. (PubMed, J Neuroinflammation) - "Diet-facilitated microbial production of acetate and butyrate attenuates behavioral deficits of LTNI after TBI and produces enduring benefits at the single-cell level on the neuro-inflammatory and neuro-progenitor responses. This therapeutic approach could have a broader potential to prevent neurodegenerative disease."

Journal • Alzheimer's Disease • CNS Disorders • Inflammation • Vascular Neurology

Study on How Nerve Signalling is Affected by a High-Fibre Supplement in Untreated Hypertensive Individuals. (ANZCTR) - P=N/A | N=29 | Not yet recruiting | Sponsor: Professor Francine Marques - Monash University

New trial • Cardiovascular • Hypertension

Safety and effects of acetylated and butyrylated high-amylose maize starch on youths recently diagnosed with type 1 diabetes: A pilot study. (PubMed, Diabetes Obes Metab) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Effect of Prebiotics on the Gut Microbiome Profile and Beta Cell Function (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: Indiana University | Phase classification: P3 ➔ P1

Phase classification • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • IL2RA • ISG20

HAMSAB diet ameliorates dysfunctional signaling in pancreatic islets in autoimmune diabetes. (PubMed, iScience) - "Finally, SCFA increased insulin levels in human β-like cells and improved transplantation outcome in NOD/SCID mice. Our findings support the use of metabolite-based diet as attractive approach to improve glucose control in T1D."

Journal • Diabetes • Immunology • Metabolic Disorders • Obesity • Transplantation • Type 1 Diabetes Mellitus

HAMS-AB-01B: HAMS-AB in Newly Diagnosed Patients With Type 1 Diabetes (clinicaltrials.gov) - P1 | N=39 | Not yet recruiting | Sponsor: Rise Therapeutics LLC

New P1 trial • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus